Loading organizations...
§ Private Profile · Manhattan Beach, CA, USA
Medical device developer creating minimally invasive devices for severe venous disease and venous insufficiency in the legs.
Key people at InterVen Partners.
InterVene develops minimally invasive medical devices for treating severe venous disease in the legs. The company's primary focus is on identifying and addressing critical clinical needs within vascular disease through innovative solutions, exemplified by its flagship product, the BlueLeaf System. This system, which aims to provide advanced, less invasive treatment for severe venous insufficiency, was initially conceived during a Stanford Biodesign Fellowship, underscoring the company's origins in academic medical innovation and problem-solving. As a graduate of the Fogarty Institute, InterVene operates within the specialized medical device sector, targeting patients requiring advanced, less invasive options for complex vascular conditions. The organization is led by its Founder and CEO, Fletcher Wilson. InterVene was established by Fletcher Wilson following the completion of his Stanford Biodesign Fellowship.
Key people at InterVen Partners.
InterVen Partners is a private investment firm known for making targeted investments in companies, such as a $1.5 million stake for a substantial minority interest in a business as noted in 1988 reporting.[3] Limited public information exists on its mission or philosophy, but it aligns with private equity practices involving minority stakes rather than majority control or broad fund management.[3] It does not appear focused on specific key sectors like specialty finance or middle-market buyouts seen in similar firms, and its impact on the startup ecosystem is unclear from available data, with no prominent track record of portfolio companies or ecosystem influence documented.[1][2][3][4]
InterVen Partners emerges in historical records from at least 1988, when it executed a $1.5 million investment acquiring a substantial minority interest in an unnamed company, as reported by the Los Angeles Times.[3] No details on founding year, key partners, or evolution of focus are available in search results, distinguishing it from better-documented firms like InterVest (founded with 25+ years track record in specialty finance) or Aterian (established 2009).[1][2] This single reference suggests early-stage private investment activity without further backstory on founders or pivotal moments.
InterVen Partners' limited visibility places it outside major trends in private equity, such as flexible capital for software/IT or middle-market transformations riding digital innovation and analytics.[4][5] Timing from its 1980s activity predates modern tech booms, with no evidence of influence on startup ecosystems amid market forces like AI-driven investments or principal investor strategies.[5] It does not shape broader dynamics seen in global firms optimizing fund operations or portfolio value creation.[1][4][5]
With scant recent data, InterVen Partners' trajectory remains opaque—potentially dormant or rebranded, unlike active players expanding in private equity amid efficiency and digital trends.[5] Evolving influences like analytics-driven strategies could reshape similar minority investors, but without updates, its role may stay marginal.[5] This ties back to its core as a niche 1980s-era investor, warranting deeper proprietary research for current relevance.[3]
